Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 19/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660039 | 0.87 | GCK (0.61) | GCKKCNH2 | |
| SCHEMBL2660044 | 0.85 | GCK (0.59) | GCKKCNH2 | |
| SCHEMBL3347912 | 0.85 | GCK (0.59) | GCKKCNH2 | |
| SCHEMBL2660045 | 0.85 | GCK (0.59) | GCKKCNH2 | |
| SCHEMBL2650648 | 0.85 | GCK (0.78) | GCKKCNH2 | |
| SCHEMBL2659081 | 0.84 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2899445 | 0.84 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL4773355 | 0.84 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2655074 | 0.84 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2652823 | 0.83 | GCK (0.69) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA UK LIMITED AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA UK LIMITED AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA UK LIMITED AB (SE) | 2010-06-24 | — | — | US | disclosed |
| EP-1915367-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | GCK, GCKR, HK1 | GCK 1/4885KCNH2 1322/4885PTGER1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.